Ris­ing Penn star Saar Gill gets fund­ing for a next-gen CAR-T start­up, adding a new weapon to the mix

Ear­li­er this month, the Uni­ver­si­ty of Penn­syl­va­nia’s Saar Gill turned up at AS­CO to present new da­ta demon­strat­ing that a com­bi­na­tion of Im­bru­vi­ca with No­var­tis’ next-gen CAR-T CTL119 proved very ef­fec­tive in treat­ing par­tic­u­lar­ly lethal cas­es of chron­ic lym­pho­cyt­ic leukemia, wip­ing out all signs of the dis­ease in 8 of 9 treat­ment-re­sis­tant pa­tients en­rolled in an ex­plorato­ry study.

But Gill’s been par­tic­u­lar­ly busy on the CAR-T front, and not just in new re­search work. He’s al­so been en­list­ing some mar­quee in­vestors on a new start­up project that will aim at mak­ing a ma­jor new ad­vance in the field.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER